(Press-News.org) Contact information: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
New eye treatment effective in laboratory tests
Promising new approach may lead to treatments for common eye diseases like neovascular macular degeneration and diabetic retinopathy
LA JOLLA, CA – October 23, 2013 – A promising technique for treating human eye disease has proven effective in preclinical studies and may lead to new treatments to prevent blindness, according to experiments conducted at The Scripps Research Institute (TSRI) in La Jolla, California.
The studies involved controlling the actions of microRNAs, tiny pieces of RNA that were once considered to be "junk" but are now known to fine-tune gene activation and expression. The researchers showed that treating mice with short RNA strands that precisely target and inhibit microRNAs ("antimicroRNAs") can stop the aberrant growth of blood vessels ("neovascularization").
It is this abnormal proliferation of vessels that exacerbates vision loss in neovascular eye diseases like "wet" macular degeneration and diabetic retinopathy, two of the leading causes of blindness.
Described in the cover story of the November issue of the Journal of Clinical Investigation, the microRNA treatments blocked aberrant vessel growth without damaging existing vasculature or neurons in three separate models of neovascular eye disease—a proof-of-principle that suggests future treatment based on the same approach may be effective in humans.
"We believe that targeting and inhibiting the action of microRNAs involved could represent a novel and effective way to treat a broad range of neovascular eye diseases such as diabetic retinopathy, macular degeneration and macular telangiectasia," said TSRI Professor Martin Friedlander, MD, PhD, who was senior author of the study. "We are excited about this approach to halting abnormal blood vessel growth without inducing off-target side effects."
The work is the first published result of a five-year, $10.2 million grant awarded last year by the National Eye Institute of the National Institutes of Health. The grant aims to harness the potential of microRNAs to stop abnormal blood vessel sprouting in the back of the eye and prevent blindness.
Friedlander said that the researchers hope to advance this approach with clinical trials; a potential pharmaceutical partner is interested in partnering with them once the therapy is optimized for human use. Clinical trials may take several years, and any such treatment would have to prove safe and effective before it would be routinely available.
"Are we ready to go to the clinic tomorrow?—no," said Friedlander. "But is this class of therapeutics 'druggable'—the answer is 'yes.'"
Diseases Tied to Protein Called VEGF
Many types of blindness can be tied directly to the abnormal growth of blood vessels in the back of the eye—the retina, a soft tissue already rich with vasculature and crowded with light-sensing cells that capture visual cues and send signals to the brain.
In diseases like "wet" macular degeneration and diabetic retinopathy, abnormal blood vessels proliferate under or on top of the retina, respectively, presumably in response to hypoxia, or low oxygen levels. While the precise cause of the hypoxia is not clear, in the case of macular degeneration it may be due to deposits of abnormal molecules leading to inflammation and neovascularization. In diabetic retinopathy, scientists believe that the vessels themselves function abnormally, leaking fluid and bleeding, leading to loss of vision and the growth of additional abnormal vessels.
For many years, scientists have sought to address vision loss by stemming this sort of aberrant growth of blood vessels. In the last decade, much of the focus has been on a molecule found in the human body called VEGF (vascular endothelial growth factor).
VEGF is central to many types of aberrant blood vessel growth. When the body senses too little oxygen, it produces VEGF, and when vessels in the eye sense the elevated levels of that molecule, they sprout new shoots. VEGF and other molecules that promote blood vessel growth activate Ras, a gene that has to be activated for blood vessel sprouting to occur. Stopping VEGF, scientists have thought, would be a viable way to prevent blindness in many people.
The pharmaceutical industry has been hotly pursuing ways to block the action of VEGF in people at risk of blindness and for other diseases as well, including cancer. Tumors often overproduce VEGF to stimulate blood vessel growth within tumors so that their fast-dividing cells are kept supplied with oxygen and other nutrients. Several anti-VEGF drugs (such as Lucentis® (ranibizumab), Macugen (pegaptanib), Eylea® (aflibercept) and Avastin® (bevacizumab)) are already in use, and dozens more are in clinical trials against cancers and common eye disorders such as wet macular degeneration.
Blocking VEGF in eye diseases has proved to be complicated, however. In addition to stimulating the growth of new blood vessels and mediating vascular permeability, the molecule also plays a critical function in maintaining the health of nerve cells and blood vessels in the retina, so disabling it too much can create unintended consequences within the eye's delicate tissues.
A New Approach
Last year, in another paper published in the Journal of Clinical Investigation, Friedlander and his colleagues showed that VEGF is critically important for maintaining healthy vision as well and that blocking it completely can kill the eye's light-sensing cells, actually causing severe vision loss. (Friedlander's lab has investigated a number of other, non-VEGF angiogenic pathways and has shown that combining antagonists of these pathways along with a VEGF antagonist can actually enhance anti-angiogenic activity when used as combination therapy.)
"Our collaborator, David Cheresh, and his lab observed that microRNAs could be used to target neovascularization at a point in the pathway 'downstream' of VEGF," said Peter Westenskow, PhD, a postdoctoral fellow at TSRI and first author of the new study. "We have now shown that microRNAs can inhibit the actions of multiple pro-angiogenic compounds including, but not limited to, VEGF. Blocking these 'downstream' targets would stop the aberrant blood vessel sprouting while maintaining the health of the normal blood vessels in the eye."
In the new study, the team focused on microRNA-132, blocking it in the eye and preventing Ras activation using a tiny 22-base anti-microRNA. This work was the first to test its effect for neovascular eye diseases, showing that the new approach inhibited angiogenesis in three different models of neovascular eye disease.
The researchers believe this work is especially promising, as other anti-microRNA-based therapies for different diseases are already in clinical trials.
INFORMATION:
The article, "Ras pathway inhibition prevents neovascularization by repressing endothelial cell sprouting," by Peter D. Westenskow, Toshihide Kurihara, Edith Aguilar, Elizabeth L. Scheppke, Stacey K. Moreno, Valentina Marchetti, Iacovos P. Michael, Sudarshan Anand, Andras Nagy, David Cheresh and Martin Friedlander appears in the Journal of Clinical Investigation. See: http://www.jci.org/articles/view/70230
This work was funded by the National Institutes of Health (grants EY022025-01, EY11254, CA50286, HL103956 and EY021416). Additional support was provided by the Lowy Medical Research Institute and via a fellowship from the Manpei Suzuki Diabetes Foundation and the Japan Society for the Promotion of Science Postdoctoral Fellowship for Research Abroad.
New eye treatment effective in laboratory tests
Promising new approach may lead to treatments for common eye diseases like neovascular macular degeneration and diabetic retinopathy
2013-10-23
ELSE PRESS RELEASES FROM THIS DATE:
Changes in epigenetic DNA functions reveal how diabetes predisposes individuals to Alzheimer's
2013-10-23
Changes in epigenetic DNA functions reveal how diabetes predisposes individuals to Alzheimer's
Mount Sinai researchers hope to exploit findings to develop novel preventive and treatment strategies for Alzheimer's disease
New ...
Swiss private banking in clinch with high cost level
2013-10-23
Swiss private banking in clinch with high cost level
For the international wealth management industry, 2012 was a more benign year than the harsh 2011. Due to favorable stock and bond markets the volumes of managed funds increased, though not returning to pre-crisis ...
The molecular clock of the common buzzard
2013-10-23
The molecular clock of the common buzzard
Bielefeld biologists reveal the influence of genes on dispersal behavior
This news release is available in German. Be it hibernation or the routes of migratory birds: all animal behaviour that is subject to annual ...
Nanopore opens new cellular doorway for drug transport
2013-10-23
Nanopore opens new cellular doorway for drug transport
A living cell is built with barriers to keep things out – and researchers are constantly trying to find ways to smuggle molecules in. Professor Giovanni Maglia (Biochemistry, Molecular and Structural ...
New software traces origins of genetic disorders 20 times more accurately
2013-10-23
New software traces origins of genetic disorders 20 times more accurately
In a bioinformatics breakthrough, iMinds – STADIUS – KU Leuven researchers have successfully applied advanced artificial intelligence to enable the automated analysis of huge amounts of ...
Insights into how TB tricks the immune system could help combat the disease
2013-10-23
Insights into how TB tricks the immune system could help combat the disease
Researchers have identified a potential way to manipulate the immune system to improve its ability to fight off tuberculosis (TB).
TB is a major problem for both humans and ...
Communication with similar people stronger than believed
2013-10-23
Communication with similar people stronger than believed
People's tendency to communicate with similar people is stronger than earlier believed, which restricts the flow of information and ideas in social networks. These are the findings that an Aalto University ...
People don't put a high value on climate protection
2013-10-23
People don't put a high value on climate protection
Without further incentives selfish behavior will continue to dominate
This news release is available in German. People are bad at getting a grip on collective risks. Climate change is a good ...
Long-term memory helps chimpanzees in their search for food
2013-10-23
Long-term memory helps chimpanzees in their search for food
Searching for bountiful fruit crops in the rain forest, chimpanzees remember past feeding experiences
This news release is available in German. Where do you go when the fruits in ...
Study finds natural compound can be used for 3-D printing of medical implants
2013-10-23
Study finds natural compound can be used for 3-D printing of medical implants
Researchers from North Carolina State University, the University of North Carolina at Chapel Hill and Laser Zentrum Hannover have discovered that a naturally-occurring compound ...
LAST 30 PRESS RELEASES:
Attitudes, not income, drive energy savings at home
The playbook for perfect polaritons
‘Disease in a dish’ study of progressive MS finds critical role for unusual type of brain cell
Solar-powered method lights the way to a ‘de-fossilized’ chemical industry
Screen time linked to lower academic achievement among Ontario elementary students
One-year outcomes after traumatic brain injury and early extracranial surgery in the TRACK-TBI Study
Enduring outcomes of COVID-19 work absences on the US labor market
Affirmative action repeal and racial and ethnic diversity in us medical school admissions
Cancer progression illuminated by new multi-omics tool
Screen time and standardized academic achievement tests in elementary school
GLP-1RA order fills and out-of-pocket costs by race, ethnicity, and indication
Study finds HEPA purifiers alone may not be enough to reduce viral exposure in schools
UVA Health developing way to ID people at risk of dangerous lung scarring even before symptoms appear
How can we know when curing cancer causes myocarditis?
Male infertility in Indian men linked to lifestyle choices and hormonal imbalances
An acoustofluidic device for sample preparation and detection of small extracellular vesicles
The advent of nanotechnology has ushered in a transformative era for oncology, offering unprecedented capabilities for targeted drug delivery and controlled release. This paradigm shift enhances thera
A prototype LED as thin as wallpaper — that glows like the sun
Transnational electoral participation of undocumented Mexican immigrants in the US
A new method to build more energy-efficient memory devices for a sustainable data future
Freely levitating rotor spins out ultraprecise sensors for classical and quantum physics
‘Chinese lantern’ structure shifts into more than a dozen shapes for various applications
Towards light-controlled electronic components
Tiny architects, titanic climate impact: scientists call for October 10 to become International Coccolithophore Day
Stress sensitivity makes suicidal thoughts more extreme and persistent among the university population
Lessons from Ascension’s shark troubles could help boost conservation
Fire provides long-lasting benefits to bird populations in Sierra Nevada National Parks
Menstrual cycle affects women’s reaction time but not as much as being active
Housing associations more effective than government in supporting unemployed in deprived areas
Biochar helps composting go greener by cutting greenhouse gas emissions
[Press-News.org] New eye treatment effective in laboratory testsPromising new approach may lead to treatments for common eye diseases like neovascular macular degeneration and diabetic retinopathy